881673-67-2

Usage

Molecular Structure

1H-Pyrrole-3-carboxaldehyde, 1-[(4-methylphenyl)sulfonyl]-5-[2-(trifluoromethyl)phenyl]consists of a pyrrole ring with a carboxaldehyde group (-CHO) and a sulfonyl group (-SO2R) attached to it. The pyrrole ring is a five-membered aromatic ring with one nitrogen atom and four carbon atoms.

Substituents

The compound contains a 4-methylphenyl group (a phenyl ring with a methyl group attached to the 4th carbon) and a 2-(trifluoromethyl)phenyl group (a phenyl ring with a trifluoromethyl group attached to the 2nd carbon).

Applications

This chemical may have applications in organic synthesis, medicinal chemistry, and material science. It could potentially be used as a building block for the synthesis of pharmaceutical drugs or advanced materials.

Research Interest

The properties of 1H-Pyrrole-3-carboxaldehyde, 1-[(4-methylphenyl)sulfonyl]-5-[2-(trifluoromethyl)phenyl]may be of interest for researchers in various scientific fields, as it can provide insights into the behavior of complex organic molecules and their potential applications in different industries.

Upstream product

• 881673-54-7 ethyl 5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate 
• 881673-68-3 ethyl 2-chloro-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate 
• 54109-16-9 2-(trifluoromethyl)phenacyl bromide 
• 881673-53-6 ethyl 2-cyano-4-oxo-4-[2-(trifluoromethyl)phenyl]butanoate 

Downstream Products

• 881678-65-5 N-methyl-1-{{1-(4-methylphenyl)sulfonyl}-5-[2-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methanamine hydrochloride 

Relevant academic research and scientific papers

Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action

With the aim to find a novel long-lasting potassium-competitive acid blocker (P-CAB) that would perfectly overcome the limitations of proton pump inhibitors (PPIs), we tried various approaches based on pyrrole derivative 1b as a lead compound. As part of

Proton pump inhibitors

A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R 2 , R 3 and R 4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R 5 and R 6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.

PROTON PUMP INHIBITORS

A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.